153 related articles for article (PubMed ID: 11811215)
1. Etanercept: anti-tumor necrosis factor therapy for rheumatoid arthritis.
McGahan L
Issues Emerg Health Technol; 1999 Oct; (8):1-6. PubMed ID: 11811215
[No Abstract] [Full Text] [Related]
2. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.
Kekow J; Welte T; Kellner U; Pap T
Arthritis Rheum; 2002 Mar; 46(3):843-4. PubMed ID: 11920425
[No Abstract] [Full Text] [Related]
3. Anti-tumour necrosis factor therapy in the West Midlands.
Bartram D; Sheeran T; Price T; Mulherin D
Rheumatology (Oxford); 2004 Mar; 43(3):400; author reply 400-1. PubMed ID: 14963219
[No Abstract] [Full Text] [Related]
4. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis.
Bliddal H; Terslev L; Qvistgaard E; Konig M; Holm CC; Rogind H; Boesen M; Danneskiold-Samsøe B; Torp-Pedersen S
Scand J Rheumatol; 2006; 35(5):341-5. PubMed ID: 17062431
[TBL] [Abstract][Full Text] [Related]
5. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
6. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
7. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
8. The miracle of motion: two new drugs target not just the horrific pain of rheumatoid arthritis, but the disease itself.
Kalb C
Newsweek; 1999 Oct; 134(14):63. PubMed ID: 10620974
[No Abstract] [Full Text] [Related]
9. Etanercept in rheumatoid arthritis.
Escalante A; del Rincón I
N Engl J Med; 1999 Jun; 340(25):2000; author reply 2001. PubMed ID: 10383274
[No Abstract] [Full Text] [Related]
10. New-onset psoriasis associated with etanercept therapy.
Chen LA; Su LH; Chang YJ; Hsu YL; Tsai TH
J Dermatol; 2010 Apr; 37(4):378-80. PubMed ID: 20507411
[No Abstract] [Full Text] [Related]
11. [Etanercept for therapy of rheumatoid arthritis].
Miyasaka N
Nihon Rinsho; 2005 Jan; 63 Suppl 1():521-5. PubMed ID: 15799411
[No Abstract] [Full Text] [Related]
12. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
13. Etanercept-associated SLE with lupus nephritis.
Neradová A; Stam F; van den Berg JG; Bax WA
Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471
[No Abstract] [Full Text] [Related]
14. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
15. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
Kaliterna DM
Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
[TBL] [Abstract][Full Text] [Related]
16. Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
Taiwo B; Lee C; Venkat D; Tambar S; Sutton SH
Arthritis Rheum; 2007 Feb; 57(1):179-81. PubMed ID: 17266091
[No Abstract] [Full Text] [Related]
17. Treatment of rheumatoid arthritis with etanercept.
Genovese MC; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
[TBL] [Abstract][Full Text] [Related]
18. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
Lai JH
J Microbiol Immunol Infect; 2005 Dec; 38(6):451-4. PubMed ID: 16341348
[No Abstract] [Full Text] [Related]
19. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
Wolfe F; Michaud K
Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
[TBL] [Abstract][Full Text] [Related]
20. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
[Next] [New Search]
